Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 801–900 of 1,000
Guan, Y., Shen, G., Fang, Q., Xin, Y., Huo, X., Li, J., Zhao, F., Ren, D., Liu, Z., Li, Z., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00814-3 · Cited by 13
Helmy, M. W., Youssef, M. H., Yamari, I., Amr, A., Moussa, F. I., Wakil, A. E., Chtita, S., El‐Samad, L. M., & Hassan, M. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-76947-0 · Cited by 13
The molecular landscape of AL amyloidosis
Zvida, T., Muchtar, E., Dispenzieri, A. A., Shpilberg, O., & Hershkovitz‐Rokah, O. (2025) · British Journal of Haematology · doi:10.1111/bjh.20070 · Cited by 14
“59 It forms complexes with cyclin-dependent kinase (Cdk) 4 and Cdk6, which are necessary for cell cycle progression and for inactivating retinoblastoma protein (pRB), thereby promoting gene activity and facilitating cell cycle transition.”
Kim, H., Park, G. H., Park, S. B., Kim, J. D., Eo, H. J., Son, H.-J., Song, J. H., & Jeong, J. B. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2453-4 · Cited by 13
“CDK4 and 6 induces phosphorylation of retinoblastoma protein which promotes the progression of cell cycle [7].”
BackgroundDevelopment of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
Berg, H. F., Ju, Z., Myrvold, M., Fasmer, K. E., Halle, M. K., Høivik, E. A., Westin, S. N., Trovik, J., Haldorsen, I. S., Mills, G. B., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0745-6 · Cited by 13
Zhu, Y.-J., Qu, X., Zhan, D., Chen, H., Li, H., Liu, L., Chen, X., Liu, Y., Li, Y., Bai, J., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.003 · Cited by 14
Zhu, G., Li, X., Li, J., Zhou, W., Chen, Z., Fan, Y., Jiang, Y., Zhao, Y., Sun, G., & Mao, W. (2020) · Journal of Cancer · doi:10.7150/jca.47111 · Cited by 15
“Cyclin D1 depletion is known to cause both G1/S and G2/M cell cycle arrests, which is regulated by the cyclin D1CDK4/6 and cyclin D1-Chk1-Cdc25-Cdc2 pathway under oxidative stress respectively [22, 23].”
BackgroundKafri, N. A., & Hafizi, S. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101111 · Cited by 13
Jiang, G., Mohideen, A. P., Seshadri, V. D., & Rengarajan, T. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.07.005 · Cited by 14
Liu, Y., Shi, Z., Zheng, J., Zheng, Z., Sun, H., Xuan, Z., Bai, Y., Fu, M., Du, Y., & Shao, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171883 · Cited by 13
“Frontiers in Immunology 14 of cancer phenotype and disease development (42).”
BackgroundCyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population
Hu, Z., Zhou, Z., Guolian, X., Wang, Y., Lai, Y., Deng, L., & Yang, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-1741-3 · Cited by 13
“Hence, CCND1 has been regarded as a potential target for tumor therapy [12].”
BackgroundKomers, R., Xu, B., Fu, Y., McClelland, A., Kantharidis, P., Mittal, A. K., Cohen, H. T., & Cohen, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096987 · Cited by 16
“Cyclin D1 promotes the G1/S transition of the cell cycle and thereby also increases proliferation [84].”
BackgroundMeasuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry
Fleisig, H. B., & Wong, J. M. Y. (2012) · Journal of Visualized Experiments · doi:10.3791/4045-v · Cited by 13
DeMicco, A., Reich, T. J., Arya, R. S., Rivera-Reyes, A., Fisher, M. R., & Bassing, C. H. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1198861 · Cited by 13
Omar, H. A., & Tolba, M. F. (2018) · IUBMB Life · doi:10.1002/iub.1743 · Cited by 13
“Cyclin D1 plays an important role in cell cycle regulation as an inducer of cell proliferation (36).”
BackgroundImaging Tumor Proliferation in Breast Cancer
Elmi, A., McDonald, E. S., & Mankoff, D. A. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.007 · Cited by 13
Chen, Y., Liu, F., Wu, K., Wu, W., Wu, H., & Zhang, W. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3056 · Cited by 13
“When cyclin D1 is activated, the cell cycle is initiated.(25,26) When cyclin D1 is inactivated, the process of the cell cycle may be suppressed.”
BackgroundHuang, W., & Wang, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-52 · Cited by 14
“Cyclins could allosterically activate the cognate CDKs through formation of cyclin-CDK complexes, which contribute to cell cycle progression (32,52).”
BackgroundInfluentialHuang, S.-W., Sun, M.-T., Lee, W., Su, Y.-S., Lee, Y., Chiang, M., Wang, Y.-C., Yang, Y., Tzeng, S., Wu, T., et al. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.12.008 · Cited by 13
Zhang, F., Li, Q., Wu, J., Ruan, H., Sun, C., Zhu, J., Song, Q., Xu, W., Shi, Y., & Zhu, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920931 · Cited by 15
PP2ACdc55regulates G1cyclin stability
McCourt, P. C., Ebert, C., Yan, G., Jiang, Y., & Nickels, J. T. (2013) · Cell Cycle · doi:10.4161/cc.24231 · Cited by 18
“Of the three D-type cyclins (D1, D2, D3), cyclin D1 is the most frequently overexpressed in human cancers.(5) While mechanisms increasing D1 expression, such as gene amplification and altered transcription, are known, it is the loss of cyclin degradation that is thought to be the leading cause of overexpression.”
BackgroundPark, G. H., Hong, S. C., & Jeong, J. B. (2016) · 한국자원식물학회지 · doi:10.7732/kjpr.2016.29.3.297 · Cited by 13
“The ability of cyclin D1 to activate G1-to-S phase transition by forming the complex with CDK4 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target (Musgrove et al., 2011).”
BackgroundSingh, A. N., & Sharma, N. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s144725 · Cited by 13
“CCND2 is another important identified cell cycle regulator required for cell cycle G1/S transition.(51) Other cell cycle genes such as CD44,(52) HIC1(53) and PTGS2(54) identified in our analysis have been reported to be frequently methylated during PCa progression.”
BackgroundLimb-bud and Heart Overexpression Inhibits the Proliferation and Migration of PC3M Cells
Liu, Q., Li, E., Huang, L., Cheng, M., & Li, L. (2017) · Journal of Cancer · doi:10.7150/jca.21375 · Cited by 13
Personalized targeted therapy for esophageal squamous cell carcinoma
Chen, X. L., D’Amico, T. A., Chen, K., Li, Y., Kang, X., & Li, J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vvft-ad29 · Cited by 13
Zhou, T. Y., Zhu, X., Ji, X., He, J., & Zhao, K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141678 · Cited by 12
Dynarowicz, K., Bartusik‐Aebisher, D., Czech, S., Kawczyk‐Krupka, A., & Aebisher, D. (2026) · Cancers · doi:10.3390/cancers18030361 · Cited by 13
“S transition in the absence of external proliferative cues [30,34,35].”
Abductive Network Action Inference for Targeted Therapy Discovery
Biane, C., Delaplace, F., & Melliti, T. (2018) · Electronic Notes in Theoretical Computer Science · doi:10.1016/j.entcs.2018.03.006 · Cited by 12
Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
Anania, M. C., Marco, T. D., Mazzoni, M., & Greco, A. (2020) · Cancers · doi:10.3390/cancers12010129 · Cited by 13
“Cyclin D1 overexpression is mainly due to oncogenic signaling through the RTK and MEK (mitogen-activated protein kinase)-ERK (extracellular signal–regulated kinase) pathways, as well as translocation and amplification of the CCND1 gene; moreover, it may also result from deregulation of mRNA stabilization, nuclear expo…”
BackgroundGu, X., Zhou, L., Chen, L., Pan, H., Zhao, R., Guang, W., Wan, G., Zhang, P., Liu, D., Deng, L., et al. (2021) · BioMed Research International · doi:10.1155/2021/6628682 · Cited by 13
“Cyclin D1, a positive regulator of the G1/S phase of cell cycle and proliferation, is regarded as a biomarker of cancer progression [41], and its levels were enhanced in ShSLFN5 cells compared to ShCtrl cells and were suppressed in SLFN5 cells relative to Vector cells (Figure 1(g)).”
ResultRetractedYu, J., Huang, X., Cao, M., Qian, L., Shao, L., Chinnathambi, A., Alharbi, S. A., & Jian, J. (2021) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2021037951 · Cited by 12
The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
Wang, Y., Yuan, X., Li, J., Liu, Z., Li, X., Wang, Z., Wei, L., Li, Y., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.785796 · Cited by 13
“, 2012), and it is overexpressed in most cases of breast cancer (Deshpande et al., 2005; Musgrove et al., 2011).”
BackgroundHe, L., Qian, X., Ge, P., Fan, D., Ma, X., Wu, Q., Sun, J., Yang, L., Shen, J. X., & Xu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.708081 · Cited by 12
“CDK4, a member of the d-type cyclin family, which can interacted with AHR to form a complex and has been implicated in the phosphorylation of retinoblastoma gene product (Rb) and plays an important role in the G1 to S phase progression of the cell cycle (29, 30).”
BackgroundFekry, B., Ribas‐Latre, A., Drunen, R. V., Bravo, R., Shivshankar, S., Dai, Y., Zhao, Z., Yoo, S. H., Chen, Z., Sun, K., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101398r · Cited by 12
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
Rezaeian, A.-H., Inuzuka, H., & Wei, W. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.009 · Cited by 13
Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc
Masaki, T., Habara, M., Hanaki, S., Sato, Y., Tomiyasu, H., Miki, Y., & Shimada, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-40412-1 · Cited by 14
Volta, F., Monica, S. L., Leonetti, A., Gnetti, L., Bonelli, M. A., Cavazzoni, A., Fumarola, C., Galetti, M., Eltayeb, K., Minari, R., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01005-0 · Cited by 12
Pita, J. M. G., Raspé, E., Coulonval, K., Decaussin‐Petrucci, M., Tarabichi, M., Dom, G., Libert, F., Craciun, L., Andry, G., Wicquart, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1247542 · Cited by 12
“Due to its deregulation, many cancer cells are addicted to CDK4/6 activity [14].”
Lau, M. Y., Han, H., Hu, J., & Ji, C. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12084 · Cited by 13
Tabarestani, S., Ghaderian, S. M. H., Rezvani, H., & Mirfakhraie, R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0896-5 · Cited by 12
“There is compelling evidence that CCND1 overexpression, which occurs in 50–70 % of breast cancers, acts as a driving force in breast cancer development [5].”
BackgroundCuri, D. A., Beauchamp, E. M., Blyth, G. T., Arslan, A. D., Donato, N. J., Giles, F. J., Altman, J. K., & Platanias, L. C. (2015) · Oncotarget · doi:10.18632/oncotarget.5091 · Cited by 12
“We also examined whether SGI-1776 modulates polysomal mRNA levels for cyclin D1 (CCND1), a gene encoding for a protein that promotes cell proliferation and is highly expressed in different malignancies [27].”
BackgroundMarkozashvili, D., Pichugin, A., Barat, A., Camara‐Clayette, V., Vasilyeva, N. V., Lelièvre, H., Kraus‐Berthier, L., Depil, S., Ribrag, V., & Vassetzky, Y. S. (2016) · Gene · doi:10.1016/j.gene.2016.01.017 · Cited by 12
Zhao, L., Loewenstein, P. M., & Green, M. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.99 · Cited by 12
“CCND1 is frequently amplified/ overexpressed in human cancers [15], and BCL3 is a candidate proto-oncogene whose function is reportedly required for metastasis of HER2-positive breast cancer cells [16].”
BackgroundBabukumar, S., Vinothkumar, V., & Ramachandhiran, D. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1555600 · Cited by 12
Identification of novel functions of the ROCK2-specific inhibitor KD025 by bioinformatics analysis
Park, J., & Chun, K. (2020) · Gene · doi:10.1016/j.gene.2020.144474 · Cited by 12
Rugo, H. S., Im, S., Joy, A. A., Shparyk, Y. V., Walshe, J. M., Sleckman, B. G., Loi, S., Theall, K. P., Kim, S., Huang, X., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.11.005 · Cited by 16
“CDKs, particularly CDK4 and CDK6 (CDK4/6), regulate cell cycle progression from the G0 or G1 phase into the S phase by phosphorylating the tumor suppressor gene retinoblastoma and other related proteins like p107 and p130 [1,3].”
BackgroundProlactin Promotes Mammary Pathogenesis Independently from Cyclin D1
Asher, J. M., O’Leary, K. A., Rugowski, D. E., Arendt, L. M., & Schuler, L. A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.041 · Cited by 12
Kwon, O., Kwak, D., Ha, S. H., Jeon, H., Park, M., Chang, Y., Suh, P., & Ryu, S. H. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.01.015 · Cited by 12
“In breast cancer cells, activation of the cyclin D1/Rb/E2F pathway is central to G0/G1 cellcycle progression [29].”
Figel, S. A., & Fenstermaker, R. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00018-8 · Cited by 13
t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65
Li, J., Liu, H., Xing, B., Yu, Y., Wang, H., Chen, G., Gu, B., Zhang, G., Wei, D., Gu, P., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0841-4 · Cited by 12
Papadakos, S. P., Chatzikalil, E., Arvanitakis, K., Vakadaris, G., Stergiou, I. Ε., Koutsompina, M.-L., Argyrou, A., Lekakis, V., Konstantinidis, I., Germanidis, G. S., et al. (2024) · Cancers · doi:10.3390/cancers16081533 · Cited by 11
“More-over, the Akt signaling pathway and cyclin D1, which are considered as basic regulators of cell survival and proliferation, and specifically the levels of phosphorylated Akt (p-Akt) and cyclin D1 (p-cyclin D1) [118,119], were negatively correlated with Cx32 expression.”
BackgroundMYCN in human development and diseases
Nishio, Y., Kato, K., Oishi, H., Takahashi, Y., & Saitoh, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1417607 · Cited by 11
Zeng, Y., Xiao, J., Shi, L., Li, Y., Xu, Y., Zhou, J., Dong, X., Hou, H., Zhong, C., Cheng, G., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117293 · Cited by 11
Martinello, R., Genta, S., Galizia, D., Geuna, E., Milani, A., Zucchini, G., Valabrega, G., & Montemurro, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236914 · Cited by 13
Liao, W., You, H.-L., Chai, C., Lee, C., Lan, C.-C. E., Chang, S., Yu, C.-L., & Yu, H. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.10.003 · Cited by 11
Janev, A., Ramuta, T. Ž., Tratnjek, L., Sardoč, Ž., Obradović, H., Mojsilović, S. B., Taskovska, M., Smrkolj, T., & Kreft, M. E. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.690358 · Cited by 11
“Next, we investigated the effect of hAM homogenate on the expression of cyclin D1, which is essential for G1/S phase transition and its overexpression had been recorded in a large proportion of human cancers, including bladder cancer (Tut et al., 2001; Musgrove et al., 2011; Choi et al., 2012; Kopparapu et al., 2013).”
BackgroundCKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy
Kim, S. J., Kim, S. T., Choi, Y. J., Kim, U. J., & Kang, K. W. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.022 · Cited by 12
“Cyclin D1 is a key regulator of the cell cycle for stimulation of S-phase entry of cells from the G 1 phase in human cancer (Musgrove et al ., 2011; VanArsdale et al ., 2015; Qie and Diehl, 2016).”
Sana, S. S., Pasha, A., Kumbhakar, D. V., Pawar, S. C., Li, H., Hou, T., Sharma, M., Gupta, V. K., & Zhang, Z. (2022) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2022.100918 · Cited by 11
Vimala, K., Asaikkutti, A., Krishnamurthy, S., & Kannan, S. (2023) · Environmental Toxicology · doi:10.1002/tox.24006 · Cited by 11
RetractedNguyen, L. T., Zimmermann, K., Kowenz‐Leutz, E., Lim, R., Hofstätter, M., Mildner, A., & Leutz, A. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.11.011 · Cited by 11
O’Mahony, F. C., Nanda, J., Laird, A., Mullen, P., Caldwell, H., Overton, I. M., Eöry, L., O’Donnell, M., Faratian, D., Powles, T. B., et al. (2013) · Journal of Visualized Experiments · doi:10.3791/50221 · Cited by 13
Liao, D. K., Wu, Y., Pu, X., Chen, H., Luo, S., Li, B., Ding, C., Huang, G., & He, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113299 · Cited by 11
“It is frequently amplified or overexpressed in cancers, such as breast cancer, lung cancer, colorectal cancer, melanoma and oral squamous cell carcinomas, through copy number PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e113299 alterations, mutation, or as a consequence of the deregulation of mit…”
BackgroundCyclin D1 splice site variant triggers chromosomal aberrations in healthy humans
Hemminki, K., Musak, L., Vymetalkova, V. P., Šmerhovský, Z., Halasova, E., Osina, O., Letková, L., Försti, A., Vodičková, Ľ., Buchancova, J., et al. (2013) · Leukemia · doi:10.1038/leu.2013.353 · Cited by 11
Oncogenes and Signal Transduction
Grumolato, L., & Aaronson, S. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00002-0 · Cited by 11
Hu, L., Wu, H., Li, B., Song, D., Yang, G., Chen, G., Xie, B., Xu, Z., Zhang, Y., Yu, D., et al. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx021 · Cited by 11
Wei, X., Zhou, J., Hong, L., Xu, Z., Zhao, H., Wu, X., & Chen, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8900 · Cited by 11
“A number of studies have demonstrated that endogenous high levels of cyclin D1 promote carcinogenesis and radioresistance in the majority of malignant tumors (22-24).”
BackgroundHe, X., Meng, F., Qin, L., Liu, Z., Zhu, X., Yu, Z., & Zheng, Y. (2019) · PubMed Central · Cited by 11
Hu, S., Liu, J., Feng, S., Wang, Y., & Liu, H. (2021) · Aging · doi:10.18632/aging.202921 · Cited by 11
“mediating G1 to S phase transition, is a well-established oncogene and important for the development and progression of several cancers [25].”
BackgroundDodurga, Y., Seçme, M., Güneş, C. E., Gündoğdu, G., Avcı, Ç. B., Bağcı, G., Küçükatay, V., & Şatıroğlu-Tufan, N. L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.10.005 · Cited by 11
“In mammalian cells, cyclin/CDK complexes regulate different cell cycle transitions and one of the most important is Cyclin D- CDK4/6 for G1 progression (Paternot et al., 2010; Musgrove et al., 2011).”
BackgroundOncogenic role of microRNA-423-5p in hepatocellular carcinoma
Wu, L.-M., Ji, J., Yang, Z., Xing, C., Pan, T., Xie, H., Zhang, F., Zhuang, L., Zhou, L., & Zheng, S. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60038-8 · Cited by 11
Female-specific rectal carcinogenesis in cyclin D1b transgenic mice
Kim, C. J., Tambe, Y., Mukaisho, K., Sugihara, H., Isono, T., Sonoda, H., Shimizu, T., Kondoh, G., & Inoue, H. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt293 · Cited by 11
Critical roles of Cyclin D1 in mouse embryonic fibroblast cell reprogramming
Oh, H., Kim, J., & Kim, J. (2016) · FEBS Journal · doi:10.1111/febs.13941 · Cited by 11
MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM.
Arnold, A. (2016) · PubMed · Cited by 11
Zhang, Y., Wang, D.-L., Yan, H., Liao, J., He, J., Hu, K., Deng, W., Wang, Y., Xing, H., Koeffler, H. P., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5975 · Cited by 11
Naaman, H., Rall, G. F., Matullo, C. M., Veksler‐Lublinsky, I., Shemer‐Avni, Y., & Gopas, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187077 · Cited by 13
Gao, Y. J., Chen, Z., Wang, R., Tan, X., Huang, C., Chen, Z., & Chen, Z. (2018) · Journal of Cancer · doi:10.7150/jca.28600 · Cited by 11
“A high expression of CD44 and Cyclin D1 is also found in some tumor cells or tissues including GC [29-32].”
BackgroundAfolabi, S. O., Olorundare, O. E., Babatunde, A. S., Albrecht, R. M., Koketsu, M., Syed, D. N., & Mukhtar, H. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6726312 · Cited by 11
“Inhibitors of cyclin D1/Cdks 4/6 complexes have been explored as therapeutic targets as this checkpoint was found deregulated in several human cancers [42].”
BackgroundSilva‐Hirschberg, C., Hartman, H., Stack, S., Swenson, S. D., Minea, R. O., Davitz, M. A., Chen, T. C., & Schönthal, A. H. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919891567 · Cited by 11
Nilsson, E. M., Brokken, L. J. S., Narvi, E., Kallio, M. J., & Härkönen, P. L. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.03.009 · Cited by 11
“It has also important cyclin-dependent kinase (CDK) -independent actions in cells through interactions with several transcription factors (Musgrove et al., 2011).”
BackgroundSun, X., Zhang, J., Zhao, Q., Chen, X., Zhu, W., Yan, G., & Zhou, T. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0316-x · Cited by 12
“Second, when combined with differentiation therapy, the identified proteins (we will specify them) may be candidate targets for reducing drug resistance [37].”
BackgroundA role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer
Ojo, D., Wu, Y., Bane, A. L., & Tang, D. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.018 · Cited by 13
Taheri, M., Abdullah, S. R., Saber, A. F., Samsami, M., & Hussen, B. M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148957 · Cited by 13
Zhang, Y., Wu, T., Li, F., Cheng, Y., Han, Q., Lu, X. B., Lü, S., & Xia, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.846744 · Cited by 12
“FGF19 Enhances the Expression of CCND1 via FGF19–FGFR4–ERK1/2 Axis in LUSC A number of growth factors are known to regulate CCND1 protein production (29, 30), and our analysis of TCGA database also found that under the background of FGF19 mRNA high expression, the frequency of CCND1mRNA high expression was elevated (F…”
BackgroundSun, X., Zheng, X., Zhang, J., Zhou, T., Yan, G., & Zhu, W. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.014 · Cited by 10
“Furthermore, these regulators could be targeted in combination with cyclin D1 inhibition therapy to reduce drug resistance [24] and induce a synergistic therapeutic effect.”
BackgroundTabarestani, S., Ghaderian, S. M. H., & Rezvani, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.17.7997 · Cited by 10
“Keywords: Amplification - MLPA - FISH - CISH - breast cancer 2010; Musgrove et al., 2011).”
BackgroundMolecular Mechanisms of Hepatocellular Carcinoma
Alotaibi, H., Atabey, N., Diril, M. K., Erdal, E., & Öztürk, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-34214-6_3 · Cited by 10
The influence of platelet membranes on tumour cell behaviour
Coupland, L. A., Hindmarsh, E. J., Gardiner, E. E., & Parish, C. R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9671-3 · Cited by 10
HIV-1 Gp120 clade B/C induces a GRP78 driven cytoprotective mechanism in astrocytoma
Acevedo, S. N. L., Rodríguez-Valentín, M., Rivera, M., Rodríguez, M., Babu, M., Cubano, L. A., Xiong, H., Wang, G., Kucheryavykh, L. Y., & Boukli, N. M. (2017) · Oncotarget · doi:10.18632/oncotarget.19474 · Cited by 11
“These results suggest that HIV-1 gp120 clade B may alter the cell cycle progression through G1/S transition with CCND1 expression, possibly contributing to further uncontrolled cell proliferation [39, 40].”
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200715 · Cited by 11
PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer
Jiang, X. L., Zhang, C., Li, W., Jiang, D., Wei, Z., Lv, M., Xie, X., & Sun, X. (2018) · Oncology Reports · doi:10.3892/or.2018.6934 · Cited by 13
Elleg�rd, S., Veenstra, C., Pérez‐Tenorio, G., Fagerstr�m, V., G�rsj�, J., Gert, K. R., Sundquist, M., Malmstr�m, A., Wingren, S., Elander, N., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.9998 · Cited by 10
“the upregulation of Cyclin D1, which regulates the G1/S-phase transition through binding to CDK 4/6 and phosphorylation of Rb (13-15).”
BackgroundTeshima, M., Tokita, K., Ryo, E., Matsumoto, F., Kondo, M., Ikegami, Y., Shinomiya, H., Otsuki, N., Hiraoka, N., Nibu, K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5452-4 · Cited by 10
Wang, L., Jin, J. Q., Zhou, Y., Tian, Z., He, B., Huang, Y., & Ding, F. (2019) · Oncology Reports · doi:10.3892/or.2019.7284 · Cited by 13
“BCL2 (37,38), cyclin D1 (39,40) and FAS (41,42) were examined using western blot analysis (Fig.”
MethodDrug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
He, H., Xu, C., Cheng, Z., Qian, X., & Zheng, L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902150555 · Cited by 11
Harbhajanka, A., Lamzabi, I., Bitterman, P., Reddy, V., Ghai, R., & Gattuso, P. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000679 · Cited by 10
“025 Nmic 1 (17) 0 1 (8) 1 (3) N1 0 7 (64) 2 (17) 6 (20) N2 0 0 1 (8) 0 N3 3 (50) 1 (9) 4 (33) 4 (13) 6 (10.”
Wang, F., Chen, G., Quinn, M. J., Chen, S., Ji, X., Shentu, Y., & Li, Y. (2019) · Europe PMC (PubMed Central) · Cited by 10
Ivanova, A. S., Tereshina, M. B., Araslanova, K. R., Martynova, N. Y., & Zaraisky, A. G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738940 · Cited by 10
Cellular Functions of Deubiquitinating Enzymes in Ovarian Adenocarcinoma
Min, Y., Park, H., Baek, K., & Hwang, S. (2023) · Genes · doi:10.3390/genes14040886 · Cited by 12
Cordani, N., Mologni, L., Piazza, R., Tettamanti, P., Cogliati, V., Mauri, M., Villa, M., Malighetti, F., Bella, C. D., Jaconi, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216294 · Cited by 10
“CDKs’ activity is tightly regulated by the INK4 (CDKN2A, 2B, 2C, and 2D) [29] and CIP/KIP protein families (CDKN1A, 1B, 1C) [30].”
BackgroundDannenmann, S. R., Hermanns, T., Bransi, A., Matter, C., von Boehmer, L., Stevanović, S., Schraml, P., Moch, H., Knuth, A. K., & van den Broek, M. F. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0113 · Cited by 10
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.